Stock comparison
Perrigo
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
PRGO
Perrigo
Market cap
$1.55B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | PRGO | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 32F | 72B | RMD |
| Benjamin Graham | 32F | 75B | RMD |
| Philip Fisher | 20F | 75B | RMD |
| Peter Lynch | 16F | 58C | RMD |
| Joel Greenblatt | 19F | 47D | RMD |
| Charlie Munger | 23F | 69B | RMD |
| Terry Smith | 14F | 73B | RMD |
Side-by-side metrics
| Metric | PRGO | RMD |
|---|---|---|
| Market cap | $1.55B | $30.18B |
| P/E (TTM) | - | 19.6x |
| EV/EBIT | 14.5x | 17.1x |
| ROIC (TTM) | 3.37% | 19.63% |
| Gross margin | 34.17% | 61.69% |
| Net margin | -43.5% | 27.44% |
| Revenue CAGR 5y | 0.68% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 1.5x | 0.1x |
| Dividend yield | 10.43% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
PRGO leads on
- P/E (TTM)-vs 19.6x+104%
- Dividend yield10.43%vs 1.14%+89%
- EV/EBIT14.5xvs 17.1x+15%
RMD leads on
- Net margin27.44%vs -43.5%+163%
- Market cap$30.18Bvs $1.55B+95%
- Revenue CAGR 5y12.64%vs 0.68%+95%
- Debt / Equity0.1xvs 1.5x+91%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.